Atomo Diagnostics Ltd
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Atomo Diagnostics Ltd (AT1) - Total Liabilities
Latest total liabilities as of December 2025: AU$2.84 Million AUD
Based on the latest financial reports, Atomo Diagnostics Ltd (AT1) has total liabilities worth AU$2.84 Million AUD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Atomo Diagnostics Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how Atomo Diagnostics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Atomo Diagnostics Ltd Competitors by Total Liabilities
The table below lists competitors of Atomo Diagnostics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BP Plastics Holding Bhd
KLSE:5100
|
Malaysia | RM48.28 Million |
|
WASHINGTON POST -B-
BE:WPOB
|
Germany | €3.35 Billion |
|
Leaf Mobile Inc
OTCQB:EAGRF
|
USA | $18.74 Million |
|
Bridgeline Digital Inc
NASDAQ:BLIN
|
USA | $6.18 Million |
|
Myotoku Ltd
MU:LXH
|
Germany | €395.34 Million |
|
BC Technology Group Limited
PINK:BCTCF
|
USA | $977.61 Million |
|
Media Chinese International Ltd
KLSE:5090
|
Malaysia | RM81.32 Million |
|
Inspirisys Solutions Limited
NSE:INSPIRISYS
|
India | ₹2.32 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Atomo Diagnostics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Atomo Diagnostics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Atomo Diagnostics Ltd (2017–2025)
The table below shows the annual total liabilities of Atomo Diagnostics Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$2.30 Million | +77.81% |
| 2024-06-30 | AU$1.29 Million | -23.11% |
| 2023-06-30 | AU$1.68 Million | -6.90% |
| 2022-06-30 | AU$1.81 Million | -15.96% |
| 2021-06-30 | AU$2.15 Million | +32.80% |
| 2020-06-30 | AU$1.62 Million | -85.94% |
| 2019-06-30 | AU$11.52 Million | -8.88% |
| 2018-06-30 | AU$12.64 Million | +6.97% |
| 2017-06-30 | AU$11.82 Million | -- |